389 related articles for article (PubMed ID: 32722309)
1. Antioxidant Therapies and Oxidative Stress in Friedreich´s Ataxia: The Right Path or Just a Diversion?
R Rodríguez L; Lapeña T; Calap-Quintana P; Moltó MD; Gonzalez-Cabo P; Navarro Langa JA
Antioxidants (Basel); 2020 Jul; 9(8):. PubMed ID: 32722309
[TBL] [Abstract][Full Text] [Related]
2. Designing phase II clinical trials in Friedreich ataxia.
Rodden LN; Lynch DR
Expert Opin Emerg Drugs; 2021 Dec; 26(4):415-423. PubMed ID: 34693848
[TBL] [Abstract][Full Text] [Related]
3. Omaveloxolone: potential new agent for Friedreich ataxia.
Lynch DR; Johnson J
Neurodegener Dis Manag; 2021 Apr; 11(2):91-98. PubMed ID: 33430645
[TBL] [Abstract][Full Text] [Related]
4. Progress in the treatment of Friedreich ataxia.
Tai G; Corben LA; Yiu EM; Milne SC; Delatycki MB
Neurol Neurochir Pol; 2018 Mar; 52(2):129-139. PubMed ID: 29499876
[TBL] [Abstract][Full Text] [Related]
5. Friedreich ataxia: a paradigm for mitochondrial diseases.
Puccio H; Koenig M
Curr Opin Genet Dev; 2002 Jun; 12(3):272-7. PubMed ID: 12076669
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis in Friedreich's Ataxia: A Metal-Induced Neurodegenerative Disease.
La Rosa P; Petrillo S; Fiorenza MT; Bertini ES; Piemonte F
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33202971
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging treatment options in the management of Friedreich ataxia.
Mancuso M; Orsucci D; Choub A; Siciliano G
Neuropsychiatr Dis Treat; 2010 Sep; 6():491-9. PubMed ID: 20856912
[TBL] [Abstract][Full Text] [Related]
8. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia.
Rodríguez-Pascau L; Britti E; Calap-Quintana P; Dong YN; Vergara C; Delaspre F; Medina-Carbonero M; Tamarit J; Pallardó FV; Gonzalez-Cabo P; Ros J; Lynch DR; Martinell M; Pizcueta P
Neurobiol Dis; 2021 Jan; 148():105162. PubMed ID: 33171227
[TBL] [Abstract][Full Text] [Related]
9. Friedreich ataxia: an update on animal models, frataxin function and therapies.
González-Cabo P; Llorens JV; Palau F; Moltó MD
Adv Exp Med Biol; 2009; 652():247-61. PubMed ID: 20225031
[TBL] [Abstract][Full Text] [Related]
10. Friedreich ataxia: the oxidative stress paradox.
Seznec H; Simon D; Bouton C; Reutenauer L; Hertzog A; Golik P; Procaccio V; Patel M; Drapier JC; Koenig M; Puccio H
Hum Mol Genet; 2005 Feb; 14(4):463-74. PubMed ID: 15615771
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological treatments for Friedreich ataxia.
Kearney M; Orrell RW; Fahey M; Brassington R; Pandolfo M
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD007791. PubMed ID: 27572719
[TBL] [Abstract][Full Text] [Related]
13. An Overview of the Ferroptosis Hallmarks in Friedreich's Ataxia.
Turchi R; Faraonio R; Lettieri-Barbato D; Aquilano K
Biomolecules; 2020 Oct; 10(11):. PubMed ID: 33126466
[TBL] [Abstract][Full Text] [Related]
14. Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids.
Cotticelli MG; Crabbe AM; Wilson RB; Shchepinov MS
Redox Biol; 2013; 1(1):398-404. PubMed ID: 25499576
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Research in Friedreich Ataxia: Unmet Needs and Opportunities.
Payne RM
JACC Basic Transl Sci; 2022 Dec; 7(12):1267-1283. PubMed ID: 36644283
[TBL] [Abstract][Full Text] [Related]
16. Friedreich ataxia- pathogenesis and implications for therapies.
Delatycki MB; Bidichandani SI
Neurobiol Dis; 2019 Dec; 132():104606. PubMed ID: 31494282
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress in inherited mitochondrial diseases.
Hayashi G; Cortopassi G
Free Radic Biol Med; 2015 Nov; 88(Pt A):10-7. PubMed ID: 26073122
[TBL] [Abstract][Full Text] [Related]
18. Friedreich's ataxia: past, present and future.
Marmolino D
Brain Res Rev; 2011 Jun; 67(1-2):311-30. PubMed ID: 21550666
[TBL] [Abstract][Full Text] [Related]
19. Treatment with ROS detoxifying gold quantum clusters alleviates the functional decline in a mouse model of Friedreich ataxia.
Villa C; Legato M; Umbach A; Riganti C; Jones R; Martini B; Boido M; Medana C; Facchinetti I; Barni D; Pinto M; Arguello T; Belicchi M; Fagiolari G; Liaci C; Moggio M; Ruffo R; Moraes CT; Monguzzi A; Merlo GR; Torrente Y
Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408077
[TBL] [Abstract][Full Text] [Related]
20. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia.
Rötig A; de Lonlay P; Chretien D; Foury F; Koenig M; Sidi D; Munnich A; Rustin P
Nat Genet; 1997 Oct; 17(2):215-7. PubMed ID: 9326946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
